Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-01-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于子公司再次获得高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its subsidiaries receiving high-tech enterprise recognition from government authorities. It discusses the impact on tax benefits and company operations but does not contain financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The document is relatively short (772 characters) and serves as a formal announcement of a corporate event related to tax status and business recognition. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a management change, voting result, or legal proceeding. The best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2019-01-18 Chinese
关于归还募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the return of raised funds that were temporarily used to supplement working capital. It details the board's approval, the use of the funds, compliance with regulations, and the full return of the funds to the designated account. The content focuses on capital usage and financing activities related to the company's fundraising proceeds. There are no financial statements or comprehensive financial data presented, nor is this an annual or interim report. The document is an update on capital usage and financing activities, fitting the Capital/Financing Update category.
2019-01-15 Chinese
关于获得政府补助资金的补充公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding government subsidies received, including detailed tables of subsidy amounts, dates, and related projects. It references accounting standards for government grants and mentions that the amounts are unaudited and subject to audit results. The document is an announcement about government subsidy funds and their expected impact on profits, not a full financial report or audit report. It is a regulatory announcement informing investors about government grants and their financial impact, without detailed financial statements or comprehensive analysis. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-01-04 Chinese
关于获得政府补助资金的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the receipt of government subsidy funds totaling approximately 80 million RMB during the period from January 1, 2018 to the announcement date. It lists detailed subsidy amounts, dates, and related projects. The document explicitly states that the data is unaudited and subject to audit results. There is no indication that this is a full financial report, audit report, or earnings release. It is a regulatory announcement about government subsidies received, which is a specific financial update but not a comprehensive financial statement or report. The document length is about 8,090 characters, which is substantial but the content is focused on subsidy receipt details. This fits best under Regulatory Filings (RNS) as a general regulatory announcement about government subsidies and financial assistance, not a formal financial report or audit.
2019-01-02 Chinese
关于公司进口分装的阿法骨化醇软胶囊被列为仿制药参比制剂的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the inclusion of their imported Alfacalcidol Soft Capsules in the National Medical Products Administration's list of reference generic drugs. It provides detailed information about the drug, its uses, and regulatory status. The document is relatively short (1105 characters) and serves as a formal disclosure to investors about a regulatory update affecting the company's product portfolio. It does not contain financial statements, management discussion, or detailed financial data. It is not a report, earnings release, or management presentation. It is a regulatory announcement informing shareholders and the market about a significant product-related regulatory event. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2019-01-02 Chinese
关于完成注册资本工商变更登记的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the completion of registration capital change and related corporate actions such as share repurchase and cancellation. It details the reduction in registered capital due to share cancellations and the completion of the business license update. The document also references prior shareholder meetings and announcements related to these changes. The content is focused on capital structure changes and corporate governance updates rather than financial results or detailed reports. The document length is short (1433 characters) and it is a formal announcement of completed capital changes, not a full financial report or management discussion. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA).
2019-01-02 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.